Labiotech.eu - Europe's leading Biotech News Website

Latest Posts

shutterstock 527246122

News and Trends 16 Jan 2017

The UK Steps Up its Game in Automated CRISPR Gene Editing

Horizon Discovery now has full access to CRISPR technology and will develop an automated gene editing platform in collaboration with Solentim. Horizon Discovery, based in Cambridge, UK, uses gene editing technology to create custom cell lines for research. To step up its game, the company has upgraded its existing license with ERS Genomics‘ to obtain […]

January 16, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

heirloom

More News! 14 Jan 2017

This Bioartist is Exhibiting Living Portraits of her own Daughters

Gina Czarnecki raises questions about identity and ownership of our own bodies through living artwork that once used to form part of other human beings. Gina Czarnecki, based in London, has used her own daughters’ cells to create unique pieces of art. In her project ‘Heirloom‘, recently exhibited at Medical Museion Copenhagen and created in collaboration […]

January 14, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

Screenshot 2017 01 12 at 6.46.14 PM 1 e1484300509836

Startup Scout 13 Jan 2017

The Good, the Bad and the Cancer-Fighting Macrophage

We decided to stick around England this week and made a short trip from London to visit the young biotech Macrophage Pharma. The company is developing immuno-oncology technology that could turn ‘bad’ tumor-associated macrophages into ‘good’, cancer-fighting cells. City: Berkhamsted, UK (near London) Founded: 2014 Employees: 1-10 Financial data: €10.38M total raised Mission: Macrophage Pharma develops next-generation immunotherapies […]

January 13, 2017 - 1 minutemin - By Clara Rodríguez Fernández

agriculture biotech rna spray bioclay

News and Trends 13 Jan 2017

RNA Spray fights Viruses and could Sidestep problems with GMOs

RNA and clay could be the future of crop protection and manipulation of plants’ traits. Researchers have managed to use these ingredients to create a spray capable of “vaccinating” plants, teaching them to recognize the genetic material of viruses. RNA-based therapies may have suffered a recent blow in the clinic this week, but when it comes […]

January 13, 2017 - 3 minutesmins - By Denise Neves Gameiro

labiotech success achievements 2016

Inside Labiotech 13 Jan 2017

Never lazy, baby! That’s what we achieved in 2016!

Bonjour to all our readers! I hope you started the new year happily and that, after all that Christmas holiday coziness, your way back into work was not too harsh! The Labiotech team is back again, too, with more optimism and vigour than ever! We took the stock of last year’s achievements and want to share with […]

January 13, 2017 - 2 minutesmins - By Philip Hemme

shutterstock 498244432

News and Trends 13 Jan 2017

UPDATE: J&J and Actelion settle on a price, R&D assets will be spun out

UPDATE (12/01/2017): J&J and Actelion have reportedly settled on a price: $260 (€245) per share, totaling more than $28 (€26) billion. The Swiss biotech’s R&D assets will be spun out into a new company that will remain independent. UPDATE (03/01/2017): The deal has veered towards splitting Actelion into two companies, one for its commercialized portfolio […]

January 13, 2017 - 4 minutesmins - By Clara Rodríguez Fernández

ADVERTISEMENT

shutterstock 551463814

News and Trends 12 Jan 2017

An Antibody to reduce Hospitalizations of Children starts Phase IIb trials

Ablynx has treated its first patient in a new trial targeting RSV infections, the main cause of children hospitalizations. Ablynx, one of the few European biotechs that made it into JP Morgan this year, develops nanobodies derived from llamas. The Belgian company announced yesterday that its candidate ALX-0171 has entered testing in Phase IIb as a treatment […]

January 12, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Screenshot 2017 01 12 at 11.39.33 AM e1484217679930

More News! 12 Jan 2017

German Microscopy Tech raises funds to take over Imaging in Biology

Luxendo has raised €8M to start international sales of its unique microscopy technology aiming to take over confocal microscopes in biology research. Luxendo, a spin-out from the European Molecular Biology Laboratory (EMBL) in Heidelberg, Germany, has closed its Series A fundraising round led by Life Science Partners (LSP), one of the best European biotech VCs. The total €8M raised will be […]

January 12, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

shutterstock 552821389

News and Trends 12 Jan 2017

Antibody Treatment for Obesity and Type 2 Diabetes enters Phase II

Novartis is initiating Phase II trials with an antibody licensed from German biotech MorphoSys that tackles the obesity and diabetes epidemic. MorphoSys is a billion euro biotech that develops therapeutic antibodies for big names like Bayer, Pfizer, GSK, Boehringer Ingelheim, Roche and Janssen. The company is now adding type 2 diabetes to its long list of indications; bimagrumab will start Phase […]

January 12, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

curevac VERSUSstudio failure

News and Trends 11 Jan 2017

Phase II Failure: CureVac’s CEO explains Missed Efficacy Endpoint

Money doesn’t guarantee success, even if it’s heavy investment from the likes of the Bill & Melinda Gates Foundation. Ingmar Hoerr explains what it means for mRNA therapeutics. In a blow to the field of mRNA, the German billion-euro biotech CureVac has reported the Phase II failure of its lead candidate at JP Morgan. Aimed at prostate cancer, CV9104 did not […]

January 11, 2017 - 4 minutesmins - By Evelyn Warner

shutterstock 550399666

News and Trends 11 Jan 2017

Merck expands its Oncology Pipeline beyond Checkpoint Inhibitors

Merck is diversifying its oncology portfolio with four new programs licensed from Vertex Pharmaceuticals, including multiple DNA damage and repair drugs. Merck has entered a licensing agreement with Boston-based Vertex Pharmaceuticals for the worldwide rights to four oncology programs. Merck has paid €220M ($230M) upfront for two clinical-stage DNA damage and repair candidates and two additional […]

January 11, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

evenfh

Best in Biotech 11 Jan 2017

UPDATE: The 5 Hottest European Biotechs in 2017 according to JP Morgan

The world’s biggest biotech investor conference, hosted by JP Morgan, is now underway in San Francisco, and European companies are putting up a strong showing. Here are those (in chronological order) who made the cut to present at this invite-only event. We’ll update the post as companies present! While uniQure has hit a number of rough […]

January 11, 2017 - 3 minutesmins - By Evelyn Warner

ADVERTISEMENT